Watchlist Price Alert

Vaxcyte Inc. (PCVX)

NASDAQ: PCVX · Real-Time Price · USD

32.51

-0.29 (-0.88%)

At close: May 30, 2025, 3:59 PM

31.37

-3.51%

After-hours: May 30, 2025, 07:26 PM EDT

-0.88% (1D)

Bid	29
Market Cap	4.19B
Revenue (ttm)	n/a
Net Income (ttm)	-509.63M
EPS (ttm)	-3.99
PE Ratio (ttm)	-8.15
Forward PE	-7.3
Analyst	Buy

Ask	32.45
Volume	1,285,872
Avg. Volume (20D)	2,500,672
Open	32.61
Previous Close	32.80
Day's Range	31.57 - 33.14
52-Week Range	27.66 - 121.06
Beta	1.27

About PCVX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PCVX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PCVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+14.17%

Shares of vaccine stocks are trading higher follow... Unlock content with Pro Subscription

3 weeks ago

+8.45%

Vaxcyte shares are trading higher after the company reported better-than-expected Q1 EPS results.

News

1 month ago · zacks.com

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

2 months ago · zacks.com

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

2 months ago · seekingalpha.com

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It...

2 months ago · benzinga.com

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (P...